KRONOS BIO INC (KRON)
US50107A1043 - Common Stock
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kronos Bio (NASDAQ:KRON) just reported results for the fourth quarter of 2023.K...
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023
KRON stock results show that Kronos Bio beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the...
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives...
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives...
Kronos Bio streamlines leadership, cuts CMO,CSO and COO roles (NASDAQ:KRON)
Kronos Bio implements a new streamlined leadership structure, eliminating three executive officer roles, to focus on pipeline advancement.
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
Company eliminates three executive officer roles and appoints new Executive Leadership team
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
Company eliminates three executive officer roles and appoints new Executive Leadership team...
Kronos ends development of larnarplenib combo therapy for AML (NASDAQ:KRON)
Kronos Bio (KROS) is discontinuing development of lanraplenib with gilteritinib for acute myeloid leukemia due to disappointing Phase 1b study results. Read more here.
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does...
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives...
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives...
Kronos Bio CEO buys common shares worth ~$1.47M (NASDAQ:KRON)
Kronos Bio (NASDAQ:KRON) disclosed on Friday that president and chief executive Norbert Bischofberger bought ~1.7M common shares at an average price of...
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
Kronos to cut 19% of workforce, focus on drugs KB-0742, lanraplenib (NASDAQ:KRON)
Kronos Bio (KRON) is cutting its workforce by 19% to focus on developing its drugs KB-0742 and lanraplenib. The cuts should extend its cash runway into 2026. Read more here.
Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study
Strategic resource allocation to fully explore KB-0742’s potential in both dose escalation and expansion cohorts across multiple tumor types in its ongoing...
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
Brian Van Tine, M.D., of Washington University School of Medicine, shares data from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds...
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
Brian Van Tine, M.D., of Washington University School of Medicine to share data from the ongoing Phase 1/2 study at leading international sarcoma meeting ...
Kronos Bio posts positive preliminary data for investigational cancer drug (NASDAQ:KRON)
Kronos Bio (KRON) on Friday announced positive preliminary data from a dose escalation portion of an ongoing early-to-mid stage trial. Read more here.